Table 1.
Characteristics of participants of the FHS without DM at the time of CF-PWV testing*
| FHS | |
|---|---|
| N | 5,676 |
| PWV, m/s | 7.3 (6.3–8.7) |
| Age, years | 46 (37–55) |
| Male sex, n (%) | 2,615 (46%) |
| Current smoker, n (%) | 846 (15%) |
| Family history of DM, n (%) | 425 (7%) |
| BMI, kg/m2 | 26 (23–29) |
| Waist circumference, in | 37 (33–40) |
| Fasting blood glucose, mg/dl | 94 (88–100) |
| Total cholesterol, mg/dl | 190 (168–215) |
| Calculated LDL, mg/dl | 113 (92–135) |
| HDL, mg/dl | 53 (43–65) |
| Triglycerides, mg/dl | 109 (77–158) |
| eGFR, ml/min/1.73m2 | 99 (87–109) |
| High-sensitivity c-reactive protein, mg/L | 1.3 (0.6–3.2) |
| SBP, mmHg | 117 (108–128) |
| DBP, mmHg | 75 (68–81) |
| MAP, mmHg | 89 (82–96) |
| Brachial PP, mmHg | 42 (36–50) |
| Central PP, mmHg | 48 (41–57) |
| Treated hypertension, n (%) | 823 (15%) |
| Number of antihypertensive medications, n (%) | |
| 1 | 586 (10%) |
| 2 | 188 (3%) |
| 3 | 38 (1%) |
| ≥4 | 11 (<1%) |
| Antihypertensive class | |
| Renin-angiotensin system blocker, n (%) | 327 (6%) |
| Thiazide diuretic, n (%) | 146 (3%) |
| Calcium channel blocker, n (%) | 178 (3%) |
| Beta blocker, n (%) | 315 (6%) |
*
Continuous variables are reported as median (IQR) and binary and categorical variables are reported as number (proportion)
Abbreviations: BMI = body mass index; CF-PWV = carotid-femoral pulse wave velocity; DBP = diastolic blood pressure; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation); FHS = Framingham Heart Study; HDL = high density lipoprotein; LDL = low density lipoprotein; MAP = mean arterial pressure; PP = pulse pressure; SBP = systolic blood pressure